Novel antidepressant drugs, arterial hypertension and cardiovascular disease.
Depression is a common mental health issue worldwide leading to disability, functional decline and increased mortality. Novel antidepressants have been developed during the last decades in order to treat depression syndromes. Some evidence suggests that major depression has been associated with the development of congestive heart failure and with adverse outcomes in patients with coronary heart disease. The purpose of the present article is to review the impact of novel antidepressant patent drugs on cardiovascular disease and arterial hypertension.
Vasiliki K
VK
Katsi
Maria
M
Marketou
Georgia
G
Vamvakou
Thomas
T
Makris
Dimitris
D
Tousoulis
Christodoulos I
CI
Stefanadis
Panos
P
Vardas
Cardiology Department, Hippokration Hospital, Greece, Vas. Sofias Avenue 114, Post code: 11527, Athens, Greece. vkkatsi@yahoo.gr.
Ioannis E
IE
Kallikazaros
D000818:Animals; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016642:Bupropion / Q000009:adverse effects / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000503:physiopathology*; D002319:Cardiovascular System / Q000187:drug effects; D003511:Cyclohexanols / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000139:chemically induced / Q000503:physiopathology*; D010330:Patents as Topic; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000069470:Venlafaxine Hydrochloride
D000928:Antidepressive Agents; D016642:Bupropion; D003511:Cyclohexanols; D017367:Selective Serotonin Reuptake Inhibitors; D000069470:Venlafaxine Hydrochloride